Week in Review: China Pharma Continues Record Deal Pace with $2 Billion in New Announcements

22:09 EDT 9 Sep 2017 | ChinaBio Today

Deals and Financings

- OrbiMed closed its third Asia private equity fund with $551 million in capital commitments, bringing its three Asia funds to almost $1 billion in total;

- Innovent Biologics of Suzhou announced a $457 million deal to acquire global rights for an immuno-therapy candidate from the Chinese Academy of Sciences;

- 3SBio of Shenyang will pay $290 million for the biologic contract development and manufacturing operations of Toronto's Therapure;

- Eight Roads, Fidelity Investment's venture arm, launched a $250 million China Healthcare Fund, its first fund dedicated to China healthcare;

- WuXi NextCODE completed a Series B fundraising with $240 million in new capital for its genomics CRO operations;

- Sisram Medical, an Israeli subsidiary of Fosun Pharma that makes laser-based aesthetic devices, will stage a $200 million Hong Kong IPO;

- Beijing's SinoVision Technologies raised $29 million in a B round to support its portfolio of CT scanners;

- Shanghai Sanyou Medical, an orthopedic medical device maker, closed a $14 million B round from Yingke Private Equity;

- China Medical Systems of Shenzhen will gain Asia rights (ex-Japan) to a MRSA candidate from Destiny Pharma, a British company;

- TPG Capital Asia acquired a majority stake in OPC Holding Company, a Taiwan company that provides clinical trial services in China and southeast Asia;

- Wuxi Fortune Pharma partnered with Andarix Pharma of Boston for China development of Tozaride, a radiolabeled cancer drug candidate;

Company News

- Lilly China notified its staff members that Lilly will close its five-year-old Shanghai R&D center, which has 200 employees, as part of a major company restructuring.  

Stock Symbols: (HK: 1530) (SHA: 600196; HK: 02196) (NYSE: LLY)

Share this with colleagues:

Original Article: Week in Review: China Pharma Continues Record Deal Pace with $2 Billion in New Announcements


More From BioPortfolio on "Week in Review: China Pharma Continues Record Deal Pace with $2 Billion in New Announcements"

Quick Search


Relevant Topics

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...